Search results for: David Michelson

Items from 1 to 20 out of 47 results

article

Pilot evaluation of a consumer wearable device to assess sleep in a clinical polysomnography trial of suvorexant for treating insomnia in patients with Alzheimer's disease

Vladimir Svetnik, Ting‐Chuan Wang, Paulette Ceesay, Ellen Snyder, more

Journal of Sleep Research > 30 > 6 > n/a - n/a

The orexin receptor antagonist suvorexant was previously reported to significantly improve total sleep time (TST), by 28 min per night versus placebo after 4 weeks, in a sleep laboratory polysomnography (PSG) study of patients with Alzheimer's disease and insomnia. The study included an exploratory evaluation of a consumer‐grade wearable “watch” device for assessing sleep that we report on here. Participants...

article

Further analyses of the safety of verubecestat in the phase 3 EPOCH trial of mild-to-moderate Alzheimer’s disease

Michael F. Egan, Yuki Mukai, Tiffini Voss, James Kost, more

Alzheimer's Research & Therapy > 2019 > 11 > 1 > 1-12

Background Verubecestat, a BACE1 inhibitor that reduces Aβ levels in the cerebrospinal fluid of humans, was not effective in a phase 3 trial (EPOCH) of mild-to-moderate AD and was associated with adverse events. To assist in the development of BACE1 inhibitors, we report detailed safety findings from EPOCH. Methods EPOCH was a randomized, double-blind, placebo-controlled 78-week trial evaluating...

article

Orexin receptor antagonists for the treatment of insomnia and potential treatment of other neuropsychiatric indications

W. Joseph Herring, Thomas Roth, Andrew D. Krystal, David Michelson

Journal of Sleep Research > 28 > 2 > n/a - n/a

In this review, we outline the role of orexin receptor antagonists in disorders of sleep/wake and other potential neuropsychiatric conditions, with a focus on suvorexant, which is currently the only approved agent in this class. The efficacy of suvorexant was established in Phase 2–3 trials with treatment durations ranging from 1 to 12 months in patients with insomnia. Suvorexant is effective at improving...

article

Suvorexant in Elderly Patients with Insomnia: Pooled Analyses of Data from Phase III Randomized Controlled Clinical Trials

W. Joseph Herring, Kathryn M. Connor, Ellen Snyder, Duane B. Snavely, more

The American Journal of Geriatric Psychiatry > 2017 > 25 > 7 > 791-802

Suvorexant is an orexin receptor antagonist approved for treating insomnia at doses of 10–20 mg. Previously reported phase III results showed that suvorexant was effective and well-tolerated in a combined-age population (elderly and nonelderly adults). The present analysis evaluated the clinical profile of suvorexant specifically in the elderly.Prespecified subgroup analyses of pooled 3-month data...

article

Clinical profile of suvorexant for the treatment of insomnia over 3 months in women and men: subgroup analysis of pooled phase-3 data

W. Joseph Herring, Kathryn M. Connor, Ellen Snyder, Duane B. Snavely, more

Psychopharmacology > 2017 > 234 > 11 > 1703-1711

Rationale Sex-related differences in the clinical profiles of some insomnia medications have been previously reported. Objective To evaluate the clinical profile of suvorexant, a novel orexin receptor antagonist approved for treating insomnia at doses up to 20 mg, by sex subgroups. Methods Efficacy analyses by sex were based on pooled data from two similar phase 3, randomized, double-blind, placebo-controlled,...

article

RELATIONSHIP BETWEEN VOLUMETRIC MRI PARAMETERS, APOE4 AND MMSE STATUS AT BASELINE IN THE VERUBECESTAT (MK-8931) MILD TO MODERATE ALZHEIMER’S DISEASE PHASE 2/3 TRIAL

Cyrille Sur, Yi Mo, James Kost, Tiffini Voss, more

Alzheimer's & Dementia > 2016 > 12 > 7(S) > P613-P614

article

BACE INHIBITOR VERUBECESTAT (MK-8931): BASELINE CHARACTERISTICS FOR PARTICIPANTS ENROLLED IN THE PHASE II/III EPOCH ALZHEIMER’S DISEASE TRIAL

Michael Egan, Tiffini Voss, Yi Mo, Yuki Mukai, more

Alzheimer's & Dementia > 2016 > 12 > 7(S) > P1183

chapter

INS/GPS localization for reliable cooperative driving

Samira Kaviani, Marie O'Brien, Jessica Van Brummelen, Homayoun Najjaran, more

2016 IEEE Canadian Conference on Electrical and Computer Engineering (CCECE) > 1 - 4

2016 IEEE Canadian Conference on Electrical and Computer Engineering (CCECE)

Cooperative driving improves vehicle safety and the driving experience by adapting the vehicle performance to the surrounding traffic. Communication of accurate and timely information obtained from multiple in-vehicle sensors, other vehicles and nearby infrastructure is essential to guarantee the robustness and reliable performance of the cooperative driving system. However, processing the information...

article

Effects of suvorexant on sleep architecture and power spectral profile in patients with insomnia: analysis of pooled phase 3 data

Ellen Snyder, Junshui Ma, Vladimir Svetnik, Kathryn M. Connor, more

Sleep Medicine > 2016 > 19 > C > 93-100

The orexin receptor antagonist, suvorexant, is approved for treating insomnia at a maximum dose of 20 mg. We evaluated its effects on sleep architecture.The analyses included pooled polysomnography data from two similar randomized, double-blind, placebo-controlled, 3-month trials evaluating two age-adjusted (non-elderly/elderly) dose regimes of 20/15 mg and 40/30 mg in 1482 patients with insomnia...

article

Suvorexant in Patients With Insomnia: Results From Two 3-Month Randomized Controlled Clinical Trials

W. Joseph Herring, Kathryn M. Connor, Neely Ivgy-May, Ellen Snyder, more

Biological Psychiatry > 2016 > 79 > 2 > 136-148

Suvorexant is an orexin receptor antagonist for treatment of insomnia. We report results from two pivotal phase 3 trials.Two randomized, double-blind, placebo-controlled, parallel-group, 3-month trials in nonelderly (18–64 years) and elderly (≥65 years) patients with insomnia. Suvorexant doses of 40/30 mg (nonelderly/elderly) and 20/15 mg (nonelderly/elderly) were evaluated. The primary focus was...

chapter

Poster

Olivera Aleksic, Milica Pejovic-Milovancevic, Smiljka Popovic-Deusic, Biljana Pirgic, more

Books of Abstracts of the 16th World Congress of the International Association for Child and Adolescent Psychiatry and Allied Professions (IACAPAP) > 253-384

Objective: One of the most powerful medications that have very broad aspects of clinical application are the selective serotonin reuptake inhibitors (SSRI). We use SSRI as a first choice agents in treatment of depression, obsessive-compulsive disorders and some anxiety disordes. Objective: To analyze the outcome of treatment of adolescent depresion with SSRI’s, considering the age group,...

chapter

Symposia

Christoph Correll, Stanley P. Kutcher, John McClellan, Jan Buitelaar, more

Books of Abstracts of the 16th World Congress of the International Association for Child and Adolescent Psychiatry and Allied Professions (IACAPAP) > 15-221

Goal: The goal of this symposium is to identify ‘state-of-the-art’ strategies for the use of antipsychotic medications in the management of children and adolescents with major psychiatric disorders. Learning objectives: 1. Define pediatric populations for whom second-generation antipsychotics are indicated 2. Identify the role of second-generation antipsychotics in the management of major psychiatric...

article

A case-control cohort study to define a threshold for the tau/abeta42 ratio in cerebrospinal fluid optimized for diagnosis of Alzheimer’s disease

Michael Egan, Yi Mo, Julie Stromswold, Kimberly Wilson, more

Alzheimer's & Dementia: The Journal of the Alzheimer's Association > 2015 > 11 > 7 Supplement > P873

article

Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: a phase 3 randomised, double-blind, placebo-controlled trial

David Michelson, Ellen Snyder, Erin Paradis, Mary Chengan-Liu, more

The Lancet Neurology > 2014 > 13 > 5 > 461-471

Suvorexant (MK-4305) is an orexin receptor antagonist shown to be efficacious for insomnia over 3 months. We aimed to assess its clinical profile during and after 1 year of treatment. We did a randomised, placebo-controlled, parallel-group trial at 106 investigational centres in the Americas, Australia, Europe, and South Africa from December, 2009, to August, 2011. Patients aged 18 years or older...

article

Communications education and training: software defined radio [Guest Editorial]

David Michelson, David Matolak, Wen Tong

IEEE Communications Magazine > 2014 > 52 > 5 > 182 - 183

This is the first in a new series of Feature Topics on Communications Education and Training that will appear regularly in IEEE Communications Magazine henceforth. It has long been appreciated that successful design, implementation, maintenance, optimization, and improvement of modern communications networks require the efforts of a highly educated, well trained, and dedicated workforce. In recent...

article

Communications education and training: expanding the student experience [Guest Editorial]

David Michelson, Maria Trocan, Wen Tong

IEEE Communications Magazine > 2014 > 52 > 12 > 96 - 97

This is the second Feature Topic on Communications Education and Training; these will appear regularly in IEEE Communications Magazine henceforth. It has long been appreciated that successful design, implementation, maintenance, optimization, and improvement of modern communications networks require the efforts of a highly educated, well trained, and dedicated workforce. In recent years, various initiatives...

article

Alertness and psychomotor performance effects of the histamine-3 inverse agonist MK-0249 in obstructive sleep apnea patients on continuous positive airway pressure therapy with excessive daytime sleepiness: a randomized adaptive crossover study

W. Joseph Herring, Kenneth Liu, Jill Hutzelmann, Duane Snavely, more

Sleep Medicine > 2013 > 14 > 10 > 955-963

We aimed to evaluate the efficacy of the selective H3 receptor inverse agonist MK-0249 to treat excessive daytime sleepiness (EDS).In this three-period, double-blind, crossover study, 125 patients (100 men, 25 women; mean age, 48.6years) with obstructive sleep apnea receiving nasal continuous positive airway pressure therapy who had refractory EDS were randomized to 2weeks each of daily MK-0249 (5,...

article

Randomized crossover study of the histamine H3 inverse agonist MK-0249 for the treatment of cognitive impairment in patients with schizophrenia

Michael F. Egan, Xin Zhao, Regina Gottwald, Lyn Harper-Mozley, more

Schizophrenia Research > 2013 > 146 > 1-3 > 224-230

Current antipsychotic treatments have little impact on the cognitive deficits associated with schizophrenia. It has been proposed that agents which promote histamine release may enhance cognition. We evaluated whether the H3 inverse agonist MK-0249 might improve cognitive deficits in patients with schizophrenia.Outpatients (N=55) with schizophrenia between ages 21 and 55 who were clinically stable,...

article

Randomized controlled study of the T‐type calcium channel antagonist MK‐8998 for the treatment of acute psychosis in patients with schizophrenia

Michael F. Egan, Xin Zhao, Andrew Smith, Matthew D. Troyer, more

Human Psychopharmacology: Clinical and Experimental > 28 > 2 > 124 - 133

ObjectiveThis study aimed to evaluate whether the T‐type calcium channel antagonist MK‐8998 was effective in treating acute psychosis in patients with schizophrenia. MethodsThis was a randomized, double‐blind, parallel‐group study. After a placebo lead‐in, acutely psychotic inpatients with schizophrenia were randomized to 4 weeks of MK‐8998 12/16 mg daily (N = 86), olanzapine 10/15 mg daily (N = 47),...

article

Long‐Term Open‐Label Safety Study of Rizatriptan Acute Treatment in Pediatric Migraineurs

David J. Hewitt, Eric Pearlman, Mirja Hämäläinen, Donald Lewis, more

Headache: The Journal of Head and Face Pain > 53 > 1 > 104 - 117

ObjectiveTo evaluate the safety/tolerability of rizatriptan in the long‐term acute treatment of migraine in pediatric patients. BackgroundAcute migraine treatment options for children are limited. A recent single‐attack trial demonstrated that rizatriptan is effective in eliminating migraine headache pain in this population. We evaluated the long‐term safety and efficacy of rizatriptan when used...

Publication date

Last 3 years (1)

Close

Date range setting

Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.

From:

To:
Set your own date range

Data set

Elsevier (30)
Springer (7)
ieee (5)
Wiley (4)
ACS (1)

Journal

Biological Psychiatry (6)
Journal of the American Academy of Child & Adolescent Psychiatry (4)
European Child & Adolescent Psychiatry (3)
Psychoneuroendocrinology (3)
Alzheimer's & Dementia (2)
Alzheimer's & Dementia: The Journal of the Alzheimer's Association (2)
IEEE Communications Magazine (2)
Journal of Sleep Research (2)
Sleep Medicine (2)
Alzheimer's Research & Therapy (1)
Drug and Alcohol Dependence (1)
Headache: The Journal of Head and Face Pain (1)
Human Psychopharmacology: Clinical and Experimental (1)
International Journal of Gynecology and Obstetrics (1)
Journal of Proteome Research (1)
Journal of Psychiatric Research (1)
Neuropsychopharmacology (1)
Pain (1)
Psychiatry Research (1)
Psychopharmacology (1)
Schizophrenia Research (1)
The American Journal of Geriatric Psychiatry (1)
The Journal of Pediatrics (1)
The Lancet (1)
The Lancet Neurology (1)
more

INFONA - science communication portal

Search results for: David Michelson

Pilot evaluation of a consumer wearable device to assess sleep in a clinical polysomnography trial of suvorexant for treating insomnia in patients with Alzheimer's disease

Further analyses of the safety of verubecestat in the phase 3 EPOCH trial of mild-to-moderate Alzheimer’s disease

Orexin receptor antagonists for the treatment of insomnia and potential treatment of other neuropsychiatric indications

Suvorexant in Elderly Patients with Insomnia: Pooled Analyses of Data from Phase III Randomized Controlled Clinical Trials

Clinical profile of suvorexant for the treatment of insomnia over 3 months in women and men: subgroup analysis of pooled phase-3 data

RELATIONSHIP BETWEEN VOLUMETRIC MRI PARAMETERS, APOE4 AND MMSE STATUS AT BASELINE IN THE VERUBECESTAT (MK-8931) MILD TO MODERATE ALZHEIMER’S DISEASE PHASE 2/3 TRIAL

BACE INHIBITOR VERUBECESTAT (MK-8931): BASELINE CHARACTERISTICS FOR PARTICIPANTS ENROLLED IN THE PHASE II/III EPOCH ALZHEIMER’S DISEASE TRIAL

INS/GPS localization for reliable cooperative driving

Effects of suvorexant on sleep architecture and power spectral profile in patients with insomnia: analysis of pooled phase 3 data

Suvorexant in Patients With Insomnia: Results From Two 3-Month Randomized Controlled Clinical Trials

Poster

Symposia

A case-control cohort study to define a threshold for the tau/abeta42 ratio in cerebrospinal fluid optimized for diagnosis of Alzheimer’s disease

Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: a phase 3 randomised, double-blind, placebo-controlled trial

Communications education and training: software defined radio [Guest Editorial]

Communications education and training: expanding the student experience [Guest Editorial]

Alertness and psychomotor performance effects of the histamine-3 inverse agonist MK-0249 in obstructive sleep apnea patients on continuous positive airway pressure therapy with excessive daytime sleepiness: a randomized adaptive crossover study

Randomized crossover study of the histamine H3 inverse agonist MK-0249 for the treatment of cognitive impairment in patients with schizophrenia

Randomized controlled study of the T‐type calcium channel antagonist MK‐8998 for the treatment of acute psychosis in patients with schizophrenia

Long‐Term Open‐Label Safety Study of Rizatriptan Acute Treatment in Pediatric Migraineurs

Filter options

Publication date

Content availability

Publication type

Keywords

Data set

Journal

INFONA - science communication portal

Search results for: David Michelson

Add recipient

Sending message cancelled

Are you sure you want to cancel sending this message?

Send message

Filter options

Publication date

Date range setting

Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.

Content availability

Publication type

Keywords

Data set

Journal

Reporting an error / abuse

Sending the report failed

Accessibility options